These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 20464498)
21. Ablating N-acetylaspartate prevents leukodystrophy in a Canavan disease model. Guo F; Bannerman P; Mills Ko E; Miers L; Xu J; Burns T; Li S; Freeman E; McDonough JA; Pleasure D Ann Neurol; 2015 May; 77(5):884-8. PubMed ID: 25712859 [TBL] [Abstract][Full Text] [Related]
22. Extensive aspartoacylase expression in the rat central nervous system. Moffett JR; Arun P; Ariyannur PS; Garbern JY; Jacobowitz DM; Namboodiri AM Glia; 2011 Oct; 59(10):1414-34. PubMed ID: 21598311 [TBL] [Abstract][Full Text] [Related]
23. Astroglial conditional Slc13a3 knockout is therapeutic in murine Canavan leukodystrophy. Hull VL; Wang Y; McDonough J; Zhu M; Burns T; Al Ramel N; Dehghani A; Guo F; Pleasure D Ann Clin Transl Neurol; 2024 Apr; 11(4):1059-1062. PubMed ID: 38282243 [TBL] [Abstract][Full Text] [Related]
24. Canavan disease. Analysis of the nature of the metabolic lesions responsible for development of the observed clinical symptoms. Baslow MH; Resnik TR J Mol Neurosci; 1997 Oct; 9(2):109-25. PubMed ID: 9407392 [TBL] [Abstract][Full Text] [Related]
25. Are astrocytes the missing link between lack of brain aspartoacylase activity and the spongiform leukodystrophy in Canavan disease? Baslow MH; Guilfoyle DN Neurochem Res; 2009 Sep; 34(9):1523-34. PubMed ID: 19319678 [TBL] [Abstract][Full Text] [Related]
26. Developmental increase of aspartoacylase in oligodendrocytes parallels CNS myelination. Kirmani BF; Jacobowitz DM; Namboodiri MA Brain Res Dev Brain Res; 2003 Jan; 140(1):105-15. PubMed ID: 12524181 [TBL] [Abstract][Full Text] [Related]
27. The effects of lithium chloride and other substances on levels of brain N-acetyl-L-aspartic acid in Canavan disease-like rats. Baslow MH; Kitada K; Suckow RF; Hungund BL; Serikawa T Neurochem Res; 2002 May; 27(5):403-6. PubMed ID: 12064356 [TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical localization of aspartoacylase in the rat central nervous system. Madhavarao CN; Moffett JR; Moore RA; Viola RE; Namboodiri MA; Jacobowitz DM J Comp Neurol; 2004 May; 472(3):318-29. PubMed ID: 15065127 [TBL] [Abstract][Full Text] [Related]
29. Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma. Tsen AR; Long PM; Driscoll HE; Davies MT; Teasdale BA; Penar PL; Pendlebury WW; Spees JL; Lawler SE; Viapiano MS; Jaworski DM Int J Cancer; 2014 Mar; 134(6):1300-10. PubMed ID: 23996800 [TBL] [Abstract][Full Text] [Related]
30. Canavan disease: a white matter disorder. Kumar S; Mattan NS; de Vellis J Ment Retard Dev Disabil Res Rev; 2006; 12(2):157-65. PubMed ID: 16807907 [TBL] [Abstract][Full Text] [Related]
31. Long-term follow-up after gene therapy for canavan disease. Leone P; Shera D; McPhee SW; Francis JS; Kolodny EH; Bilaniuk LT; Wang DJ; Assadi M; Goldfarb O; Goldman HW; Freese A; Young D; During MJ; Samulski RJ; Janson CG Sci Transl Med; 2012 Dec; 4(165):165ra163. PubMed ID: 23253610 [TBL] [Abstract][Full Text] [Related]
32. Redirecting Gessler DJ; Li D; Xu H; Su Q; Sanmiguel J; Tuncer S; Moore C; King J; Matalon R; Gao G JCI Insight; 2017 Feb; 2(3):e90807. PubMed ID: 28194442 [TBL] [Abstract][Full Text] [Related]
33. Renewal of oligodendrocyte lineage reverses dysmyelination and CNS neurodegeneration through corrected N-acetylaspartate metabolism. Lotun A; Li D; Xu H; Su Q; Tuncer S; Sanmiguel J; Mooney M; Baer CE; Ulbrich R; Eyles SJ; Strittmatter L; Hayward LJ; Gessler DJ; Gao G Prog Neurobiol; 2023 Jul; 226():102460. PubMed ID: 37149081 [TBL] [Abstract][Full Text] [Related]
34. Involvement of aspartoacylase in tremor expression in rats. Nishitani A; Tanaka M; Shimizu S; Kunisawa N; Yokoe M; Yoshida Y; Suzuki T; Sakuma T; Yamamoto T; Kuwamura M; Takenaka S; Ohno Y; Kuramoto T Exp Anim; 2016 Jul; 65(3):293-301. PubMed ID: 27026062 [TBL] [Abstract][Full Text] [Related]
35. Dietary triheptanoin rescues oligodendrocyte loss, dysmyelination and motor function in the nur7 mouse model of Canavan disease. Francis JS; Markov V; Leone P J Inherit Metab Dis; 2014 May; 37(3):369-81. PubMed ID: 24288037 [TBL] [Abstract][Full Text] [Related]
36. Effects of ethanol and of alcohol dehydrogenase inhibitors on the reduction of N-acetylaspartate levels of brain in mice in vivo: a search for substances that may have therapeutic value in the treatment of Canavan disease. Baslow MH; Suckow RF; Hungund BL J Inherit Metab Dis; 2000 Nov; 23(7):684-92. PubMed ID: 11117430 [TBL] [Abstract][Full Text] [Related]